EIGHTEEN-MONTH INTERIM ANALYSIS OF EFFICACY AND SAFETY OF GIVOSIRAN, AN RNAI THERAPEUTIC FOR ACUTE HEPATIC PORPHYRIA, IN THE ENVISION OPEN LABEL EXTENSION
D Kutera, S Keelb, C Parkerc, DC Reesd, U Stölzele, P Venturaf, M Balwanig, L Gouyah, S Rhyeei, S Silverj
a Massachusetts General Hospital, Boston, United States
b University of Washington, Seattle, United States
c University of Utah, Salt Lake City, United States
d King's College Hospital, London, United Kingdom
e Klinikum Chemnitz, Chemnitz, Germany
f Università degli Studi di Modena e Reggio Emilia, Modena, Italy
g Icahn School of Medicine at Mt. Sinai, New York, United States
j University of Michigan, Ann Arbor, United States
Ver másLido
1653
Vezesque se leu este artigo
919
Total PDF
734
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 7 | 35 | 27 | 62 |
| 2025 6 | 33 | 14 | 47 |
| 2025 5 | 31 | 16 | 47 |
| 2025 4 | 24 | 15 | 39 |
| 2025 3 | 35 | 17 | 52 |
| 2025 2 | 17 | 17 | 34 |
| 2025 1 | 22 | 21 | 43 |
| 2024 12 | 22 | 8 | 30 |
| 2024 11 | 18 | 22 | 40 |
| 2024 10 | 16 | 23 | 39 |
| 2024 9 | 18 | 15 | 33 |
| 2024 8 | 20 | 22 | 42 |
| 2024 7 | 16 | 18 | 34 |
| 2024 6 | 17 | 25 | 42 |
| 2024 5 | 17 | 25 | 42 |
| 2024 4 | 16 | 19 | 35 |
| 2024 3 | 15 | 15 | 30 |
| 2024 2 | 12 | 27 | 39 |
| 2024 1 | 14 | 20 | 34 |
| 2023 12 | 11 | 12 | 23 |
| 2023 11 | 20 | 32 | 52 |
| 2023 10 | 11 | 24 | 35 |
| 2023 9 | 14 | 32 | 46 |
| 2023 8 | 9 | 18 | 27 |
| 2023 7 | 11 | 12 | 23 |
| 2023 6 | 16 | 10 | 26 |
| 2023 5 | 15 | 23 | 38 |
| 2023 4 | 11 | 8 | 19 |
| 2023 3 | 15 | 16 | 31 |
| 2023 2 | 9 | 20 | 29 |
| 2023 1 | 6 | 8 | 14 |
| 2022 12 | 12 | 18 | 30 |
| 2022 11 | 13 | 23 | 36 |
| 2022 10 | 13 | 20 | 33 |
| 2022 9 | 18 | 32 | 50 |
| 2022 8 | 14 | 25 | 39 |
| 2022 7 | 9 | 20 | 29 |
| 2022 6 | 11 | 26 | 37 |
| 2022 5 | 16 | 22 | 38 |
| 2022 4 | 12 | 17 | 29 |
| 2022 3 | 13 | 25 | 38 |
| 2022 2 | 15 | 20 | 35 |
| 2021 1 | 16 | 27 | 43 |
| 2021 12 | 13 | 30 | 43 |
| 2021 11 | 11 | 19 | 30 |
| 2021 10 | 2 | 14 | 16 |
Mostrar tudo
